PubRank

Daniel Serin

Author PubWeight™ 31.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006 4.87
2 Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009 2.88
3 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013 2.39
4 Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2011 1.89
5 Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 2005 1.68
6 Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys 2006 1.60
7 Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010 1.52
8 Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. Ann Surg Oncol 2003 1.46
9 Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007 1.27
10 Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003 1.06
11 [For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres]. Bull Cancer 2004 1.03
12 Cancer screening in France: subjects' and physicians' attitudes. Cancer Causes Control 2007 0.99
13 Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol 2007 0.96
14 Decision-making and breast cancer clinical trials: how experience challenges attitudes. Contemp Clin Trials 2007 0.93
15 A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys 2006 0.92
16 Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res 2011 0.91
17 Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 2012 0.82
18 [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]. Bull Cancer 2012 0.81
19 Development and feasibility of a set of quality indicators relative to the timeliness and organisation of care for new breast cancer patients undergoing surgery. BMC Health Serv Res 2012 0.80
20 Impact of organised programs on colorectal cancer screening. BMC Cancer 2008 0.80
21 Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 2006 0.79
22 Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views. Int J Radiat Oncol Biol Phys 2007 0.78
23 [Physical activity and cancer survival]. Bull Cancer 2012 0.77
24 Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study. BMC Health Serv Res 2013 0.75
25 [Cancer networks]. Bull Cancer 2002 0.75
26 Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer. J Clin Oncol 2007 0.75
27 Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study. Breast 2006 0.75
28 [Surgery remains the first weapon against cancer: surgery in French cancer plan. The proposals of the group of French oncologists]. Bull Cancer 2002 0.75